Listen to the article
The U.S. Food and Drug Administration has approved a new, higher-dose version of the popular weight loss drug Wegovy, providing patients with an option that could deliver greater weight reduction benefits.
The 7.2 mg dosage, called Wegovy HD, triples the previous maximum dose of 2.4 mg and is approved for weight loss and long-term weight management in adults with obesity or overweight individuals with at least one weight-related condition.
This approval marks the fourth under the FDA’s National Priority Voucher pilot program, designed to expedite approvals addressing critical national health priorities.
“The new FDA is moving with unprecedented efficiency on products that advance national priorities,” FDA Commissioner Dr. Martin Makary said in a press release. “Today’s approval is another demonstration of what the FDA can accomplish when we try bold new things.”
Clinical data supporting the approval showed that higher doses resulted in additional weight reduction compared to previous dosing. Patients taking the higher dose experienced an average weight loss of 20.7% compared to about 16% on the standard dose, according to results from the STEP UP clinical trial. Approximately one-third of participants lost 25% or more of their body weight.
For patients with both obesity and type 2 diabetes, the higher dose showed similar blood sugar reductions compared to lower doses.
The safety profile of Wegovy HD remains consistent with known side effects of semaglutide, which commonly include gastrointestinal reactions such as nausea, vomiting, diarrhea, constipation, and abdominal pain. However, skin sensitivity, pain, or burning occurred more frequently with higher doses, though these effects generally resolved on their own or with dose reduction. The FDA continues to investigate these adverse effects.
The FDA warned that Wegovy should not be used by patients with a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or those with multiple endocrine neoplasia syndrome type 2, a rare inherited genetic disorder that causes tumors to develop in certain hormone-producing glands.
Dr. Peter Balazs, a hormone and weight-loss specialist practicing in New York and New Jersey, called the higher dosage a “major jump” but noted that the incidences of stomach- and skin-related side effects at this higher dose are “meaningful.”
“For patients who start on 2.4 mg and then hit a frustrating plateau, or for those with a very high baseline BMI who may need a stronger metabolic push, this creates a legitimate, evidence-based escalation path rather than forcing an early switch to another drug class,” said Balazs, who was not involved in the study.
Despite the approval, Balazs doesn’t expect it to “dramatically reshape the GLP-1 landscape.” He noted, “It gives Novo Nordisk an opportunity to remain competitive on efficacy while it continues developing next-generation therapies.”
This development comes as the weight loss drug market continues to expand rapidly. Drugmaker Novo Nordisk, which manufactures Wegovy, has seen unprecedented demand for its GLP-1 medications, which include both Wegovy for weight loss and Ozempic for type 2 diabetes.
Importantly, Balazs emphasized that “this approval is for obesity management, not diabetes treatment. For patients with type 2 diabetes, currently approved semaglutide dosing remains lower unless the primary treatment goal is weight loss under the obesity indication.”
The approval of Wegovy HD provides physicians with another tool in addressing America’s obesity epidemic, which affects more than 40% of U.S. adults. The condition is associated with numerous health complications, including heart disease, stroke, type 2 diabetes, and certain types of cancer.
As with all medications, patients considering Wegovy HD should consult their healthcare providers to determine if it’s appropriate for their specific situation and to understand proper usage guidelines. Healthcare professionals will need to weigh the potential benefits of greater weight loss against the possibility of increased side effects with the higher dosage.
Fact Checker
Verify the accuracy of this article using The Disinformation Commission analysis and real-time sources.
9 Comments
20.7% average weight loss is quite impressive compared to the 16% on the standard dose. If the higher-dose Wegovy proves to be safe and effective, it could make a real difference for many people dealing with obesity-related health issues.
This seems like a positive step forward, but I hope the FDA is closely monitoring for any potential side effects with the increased dosage. Weight loss is so important for health, but safety should always be the top priority.
Curious to see how the uptake of this higher-dose Wegovy will go. Weight loss can be such a struggle for many, so having more tools in the toolkit could make a real difference.
Weight loss is such an important issue, especially with the rising rates of obesity and associated health problems. Cautiously optimistic about this higher-dose Wegovy option, but will be watching for more long-term data.
This is an interesting development, but I hope the FDA is taking a very close look at the safety profile. Weight loss drugs can have some concerning side effects, so thorough vetting is crucial.
Any advancements that can help people achieve sustainable weight loss are welcome. I’m glad to see the FDA moving quickly on approvals for treatments that address critical national health priorities like this.
Agreed. The faster the FDA can get safe and effective obesity treatments to market, the better for public health.
Impressive weight loss results with the higher dose, but safety should be the top priority. Glad to see the FDA is working to expedite approvals for critical health treatments like this.
Interesting development in the fight against obesity. A higher-dose Wegovy shot could be a breakthrough for patients struggling with weight management. I’ll be curious to see the long-term safety and efficacy data as this higher dosage gets used more widely.